Curia

What Curia does

Curia Global, Inc. is a privately held Contract Development and Manufacturing Organization (CDMO) headquartered in Albany, New York, operating 20+ facilities across North America, Europe, and India with a workforce of 3,000+ professionals. Founded in 1990 as the first CRO to offer contract medicinal chemistry services, the company has evolved into an integrated CDMO providing services across four business segments: Small Molecule (discovery through commercial manufacturing), Generic APIs (150+ products from 12 GMP facilities), Biologics (antibody discovery through GMP mammalian and mRNA manufacturing), and Sterile Drug Product (clinical and commercial fill-finish for vials and prefilled syringes).

Curia's core technology platform spans proprietary flow chemistry with continuous processing capabilities, aseptic API manufacturing via closed-system isolators, fermentation from 2L to 48,000L scale, high-potency manufacturing (SafeBridge-certified for OELs below 0.1 ug/m3), and industrial chromatography from 100mL development columns to 500L commercial scale. The biologics offering includes an IP-free semi-targeted integration cell line development platform delivering 6-fold higher titers, mRNA and LNP formulation services, and GMP mammalian drug substance manufacturing. The company has filed 550+ API Drug Master Files worldwide with approvals from FDA, EMA, PMDA, KFDA, ANVISA, MHRA, and AIFA, and holds patented processes for high-value APIs including Olopatadine HCl, Etrasimod Arginine, Upadacitinib, and Deucravacitinib.

Curia's business model is fee-for-service CDMO contracts (multi-year engagements) complemented by catalog sales of generic APIs and fine chemicals (T3P reagent, vinylphosphonic acid, oxa acids, boronic acids, Gemagique AMPS polymers). The company employs an enterprise field sales motion targeting biopharmaceutical companies and generic drug manufacturers through direct engagement, industry events, and technical content marketing. Customers include 300+ sterile API clients across 30+ countries. The company is backed by private equity investor GTCR (since 2017) and completed strategic refinancing in March 2025 alongside a $200M multi-year investment in sterile fill-finish capacity expansion targeting GLP-1 and biologic demand.

Name

Curia

Legal name

Curia Global, Inc.

Website

https://curiaglobal.com

Company type

Private

Founded year

1990

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Curia is a global CDMO with 3,000+ employees and 20+ facilities providing integrated drug discovery, development, and manufacturing services across small molecule, generic APIs, biologics, and sterile drug products for biopharmaceutical companies worldwide.

Ownership category

akta.pro rank

Product category

Contract Pharmaceutical Manufacturing Services

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Chemical Manufacturing (325)

SIC

Industrial Organic Chemicals (2860)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Small-Molecule API & Intermediates CDMO (HLAGABAA), Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• Contract drug manufacturing
• Small molecule development
• Biologics manufacturing
• Sterile fill-finish
• API manufacturing

Headquarters

HQ city

Albany

HQ country

United States

HQ region

North America

Offices18 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing Services: Curia operates as a CDMO providing integrated services across drug discovery, development, and manufacturing. Revenue is generated through fee-for-service contracts for pharmaceutical companies requiring API manufacturing, sterile fill-finish, biologics manufacturing, and related services. Services are offered across clinical trial materials through commercial scale production.
2. Generic API Sales: Sale of off-patent active pharmaceutical ingredients from an extensive catalog of 150+ generic APIs covering multiple therapeutic areas including steroids, hormones, and controlled substances
3. Fine Chemicals: Sale of specialty fine chemicals including T3P reagent, vinylphosphonic acid, oxa acids, and boronic acids for pharmaceutical, agrochemical, and industrial applications

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Curia is a global Contract Development and Manufacturing Organization (CDMO) providing integrated drug discovery, development, and manufacturing services across four business units: Small Molecule, Generic APIs, Biologics, and Sterile Drug Product. The company serves biopharmaceutical clients with capabilities spanning discovery biology, medicinal chemistry, flow chemistry, fermentation, fill-finish, and commercial API manufacturing across 20+ facilities in the US, Europe, and India. It also manufactures and sells specialty fine chemicals including T3P reagent and proprietary polymers.

Product overview

Curia is a global Contract Development and Manufacturing Organization (CDMO) offering integrated services across four core business units: Small Molecule Services (spanning discovery through commercial manufacturing), Generic APIs (150+ products from 12 GMP facilities), Biologics Services (from antibody discovery through GMP mammalian and mRNA manufacturing), and Sterile Drug Product Services (clinical and commercial fill-finish). The company also manufactures and sells Fine Chemicals including T3P® reagent, Vinylphosphonic Acid, Oxa Acids, 4-FPBA, and Gemagique® polymers. Supporting capabilities include High Potency API manufacturing, Sterile API manufacturing, Steroids & Hormones production, Industrial Chromatography, Flow Chemistry, Fermentation, and Controlled Substances manufacturing. With over 30 years of experience and 20+ facilities across North America, Europe, and India, Curia provides end-to-end solutions from early drug discovery through commercial manufacturing.

Differentiator

Problem solved

Functional benefit

Brands

• Gemagique® AMPS Polymers: Cutting-edge AMPS-based polymers designed for cosmetics, personal care, and home care industries
• T3P® Reagent

Products and services

• Small Molecule Services Integrated small molecule drug discovery, development, and cGMP API manufacturing services including assay development, medicinal chemistry, DMPK, computer-aided drug design (CADD), custom synthesis, flow chemistry, high potency, sterile API, steroids and hormones, fermentation, industrial chromatography, and GMP controlled substance manufacturing. Serves pharmaceutical companies from clinical trials through commercial scale.
• Generic APIs Off-patent active pharmaceutical ingredients from a portfolio of 150+ generic APIs covering multiple therapeutic areas including steroids, hormones, and controlled substances. Manufactured across 12 GMP facilities in the US, France, Italy, Spain, and India.
• Biologics Services Comprehensive biologics capabilities from discovery through GMP manufacturing including antibody discovery and engineering, mammalian cell line development with IP-free semi-targeted integration technology, mRNA services, LNP formulation, and GMP mammalian and mRNA drug substance manufacturing.
• Sterile Drug Product Services Clinical and commercial sterile drug product manufacturing including formulation development, process development, clinical manufacturing, and commercial manufacturing. Capabilities for complex and viscous formulations, vials, and prefilled syringes across facilities in Burlington (MA), Albuquerque (NM), and Glasgow (UK).
• Analytical Testing Services Comprehensive analytical services including batch release and stability testing, method development and validation, and solid state chemistry. Supports drug substance and drug product testing across all development phases.
• T3P® Reagent (Propane-phosphonic Acid Anhydride) Propane-phosphonic acid anhydride reagent for condensation reactions including amide and peptide bond formation. Non-toxic, non-allergenic reagent with high selectivity, minimal epimerization, and exceptional product yields. ISO 9001:2015 certified production in Frankfurt, Germany.
• Gemagique® AMPS Polymers AMPS-based polymers (Ammonium Polyacryloyl Dimethyl Taurate) for cosmetics, personal care, and home care industries. Products include Gemagique HP, HPS, and CP1 with applications in creams, lotions, gels, and emulsions.
• Oxa Acids Environmentally friendly biodegradable compounds with lipophilic and hydrophilic functionalities for pharmaceuticals, cosmetics, and nanotechnology. Products include DOODS, TODS, and TUDS with applications in drug delivery, emulsifiers, and high-tech materials.
• Vinylphosphonic Acid (VPA) Innovative compound with over 20 years of production expertise for surface treatment, adhesion promotion, dispersion stability, flame retardancy, and fuel cells. VPA-based co-polymers improve proton exchange membranes for energy efficiency.
• 4-Formylphenyl Boronic Acid (4-FPBA) Versatile chemical used in detergent, pharmaceutical, and agrochemical sectors. Produced in cGMP-approved facility in Europe with capacity of several hundred tons annually. Patented manufacturing process ensures high purity for enzyme stabilization and drug synthesis.

Quantifiable outcome

• 300+ sterile API clients in 30+ countries
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

One partnership is on record.

• Apprentice.iocoreTechnology or Integration · 27 April 2026Curia expanded its partnership with Apprentice.io by selecting Apprentice as the MES (Manufacturing Execution System) platform for its Albuquerque, New Mexico site, following a successful deployment at its Rensselaer, New York facility. The expansion reflects Curia's continued investment in digital manufacturing capabilities aimed at driving greater efficiency, data visibility, and operational consistency across its network. The partnership includes access to Apprentice.io's manufacturing-specific AI agents, including their A1 autonomous AI agent designed for pharmaceutical and biotech manufacturing workflows.

Scale indicators16 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Siegfried Holding: Swiss-headquartered CDMO specializing in small molecule API manufacturing including controlled substances, steroids, and high potency. Closely comparable to Curia's small molecule API and generics business.
• Lonza Group: Global CDMO leader offering integrated small molecule and biologics services including API manufacturing, biologics, and cell and gene therapy. Directly comparable as a full-service CDMO across multiple modalities.
• Recipharm: European CDMO offering small molecule API manufacturing, sterile fill-finish, and biologics. Comparable mid-sized peer with similar service breadth and geographic footprint.
• Catalent (Novo Holdings): Major CDMO with deep capabilities in sterile fill-finish, biologics, and oral dose manufacturing. Highly comparable given Curia's recent $200M+ sterile fill-finish expansion directly competing for the same client base.
• Aenova Group: European CDMO focused on solid oral dosage forms, sterile fill-finish, and API manufacturing. Comparable in solid dose and sterile drug product capabilities.
• WuXi AppTec / WuXi Biologics: China-headquartered global CDMO offering small molecule API, biologics, and integrated discovery through manufacturing services. Direct competitor across Curia's full service stack.
• Samsung Biologics: Large-scale biologics CDMO with substantial mammalian cell culture capacity. Comparable for Curia's biologics manufacturing expansion targeting commercial-stage biologic and GLP-1 demand.
• Piramal Pharma Solutions: Global CDMO offering integrated API and drug product services across small molecules, including high potency and sterile manufacturing. Comparable as a similarly scaled multi-modality CDMO.
• Eurofins CDMO (Eurofins Discovery): Eurofins operates a CDMO franchise spanning small molecule discovery, development, and API manufacturing. Comparable in early discovery through clinical stage services.

Broad incumbents

• Thermo Fisher Scientific (Patheon CDMO): Through its Patheon CDMO business, Thermo Fisher offers comprehensive small molecule and biologics services globally. A larger diversified incumbent competing across Curia's entire portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/curia-cdmo
• Xx.com/CuriaCDMO
• Facebookfacebook.com/CuriaCDMO

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Curia